After one year of Phase III trials, Type 1 diabetes patients receiving Diapep 277 from Israel’s Andromeda Biotech, had significantly improved pancreatic performance. In the expanded trials, 450 patients were involved, from 120 medical centres across the world.
http://www.globes.co.il/serveen/globes/docview.asp?did=1000746960